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Abstract The tetraspanins associate with various surface
molecules and with each other to build a network of molecular
interactions, the tetraspanin web. The interaction of tetraspanins
with each other seems to be central for the assembly of the
tetraspanin web. All tetraspanins studied, CD9, CD37, CD53,
CD63, CD81, CD82 and CD151, were found to incorporate
[3H]palmitate. By site-directed mutagenesis, CD9 was found to
be palmitoylated at any of the four internal juxtamembrane
regions. The palmitoylation of CD9 did not influence the
partition in detergent-resistant membranes but contributed to
the interaction with CD81 and CD53. In particular, the
resistance of the CD9/CD81 interaction to EDTA, which
disrupts other tetraspanin/tetraspanin interactions, was entirely
dependent on palmitoylation. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The tetraspanins are homologous proteins characterized by
four transmembrane domains delimiting two extracellular re-
gions of unequal size, as well as a particular fold in the large
extracellular loop [1^4]. They localize at the cell surface and
for some of them within intracellular compartments [5,6]. If
the tetraspanins have various patterns of expression, all cell
types express several of them, except erythrocytes. Increasing
genetic evidence has shown the functional importance of these
molecules. For example, knock-out of CD9 has proved its
critical role in sperm^egg fusion [7^9]. Targeted deletion of
CD81 resulted in impaired lymphoid B cell function [10].
Moreover, a relation between mutations of Talla-1/TM4SF2
and certain cases of X-linked mental retardation was demon-
strated [11]. Additionally, CD81 is a co-receptor for hepatitis
C virus [12] and several tetraspanins, including CD9 and
CD82, provide a metastasis inhibitory signal [13,14] (for re-
view see [1,15]). In vitro studies have also implicated tetraspa-
nins in many cellular functions such as adhesion, migration,
co-stimulation and signal transduction [1,16].
The mechanisms that support these pleiotropic functional
observations are not understood. However, a striking prop-
erty of tetraspanins is their presence in molecular complexes
organized in di¡erent levels. Primary complexes contain one
tetraspanin linked to a speci¢c molecular partner. They com-
bine through tetraspanin/tetraspanin interactions to form
higher-order complexes that are collectively called the tetra-
spanin web [1,2]. Several of the primary complexes have been
identi¢ed, for example (tetraspanin/partner) CD81/CD19,
CD81/integrin K4L1, CD151/K3L1, CD151/K6L1, CD9 or
CD81/CD9P-1 (also called FPRP or EWI-F) and CD9 or
CD81/PGRL (also called EWI-2) [17^24]. The use of chimeric
molecules indicated that the second half of tetraspanins,
which includes the large extracellular loop, contributes to
these interactions [1]. Although a major step in the assembly
of the tetraspanin web, the way tetraspanins interact with
each other is poorly characterized, except that it does not
involve the large extracellular loop [25].
Tetraspanins are present in part in a detergent-resistant
membrane (DRM) environment, as shown by the recovery
of a fraction of these molecules into low-density fractions of
sucrose gradients after lysis with cold detergents [26^28].
These DRM were suggested to be di¡erent from previously
described cholesterol- and sphingolipid-rich lipid microdo-
mains (also called rafts [29]). These data raised the hypothesis
that the apparent association of tetraspanins could in fact
re£ect their co-localization in DRM. Targeting to rafts of
cytoplasmic molecules such as src kinases [30] and certain
transmembrane proteins [31] is dependent on fatty acylation
of the proteins (for review, see [32,33]). However, not all pal-
mitoylated transmembrane proteins are present in rafts [34],
suggesting that palmitoylation may have di¡erent roles for
other transmembrane proteins. Two tetraspanins, CD9 and
CD81, have previously been reported to be acylated [35,36].
In this paper we have demonstrated that all tetraspanins
studied are palmitoylated. Palmitoylation of CD9 occurs at
any of the four internal juxtamembrane regions and contrib-
utes to the formation and/or stabilization of interactions with
other tetraspanins, but not to its partition into DRM.
2. Materials and methods
2.1. Monoclonal antibodies
Anti-tetraspanin monoclonal antibodies (mAbs) used in this study
were SYB-1, ALB-6 (CD9), Z81 (CD81), TS53 (CD53), TS81 (CD81),
TS82, TS82b (CD82), TS151, 11B1G4 (CD151). As a negative con-
trol, we used the CD55 mAb 12A12 [21].
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2.2. Cell lines, cell culture and transfection
The lymphoid B cell lines Raji and Daudi, the megakaryocytic cell
line HEL and CHO (Chinese hamster ovary) cells were cultured as
described [18,21]. CD9-transfected Daudi and Raji cells have previ-
ously been described [17], and a similar procedure was used to obtain
Daudi cells expressing the mutant CD9 with no residual juxtamem-
brane residue (CD9plm). CHO cells were transfected as previously
reported [21].
2.3. Site-directed mutagenesis
Mutation of cysteines at juxtamembrane locations (positions 9, 78,
79, 87, 218 and 219) of CD9 cloned in pBluescript KS+ were made
with the Quickchange Kit (Stratagene) according to the manufactur-
er’s instructions. All mutants were entirely sequenced and subcloned
into pcDNA3 (Invitrogen).
2.4. Metabolic labeling with [3H]palmitate
Cells were radiolabeled as previously described by Seehafer et al.
[36]: CHO cells stably or transiently transfected with wild-type or
mutant CD9 cDNA were incubated in Petri dishes with 300 WCi/ml
[3H]palmitate (NEN, Boston, MA, USA) in RPMI 1640 containing
2% fetal calf serum (500 Wl for a 10 cm2 dish), for 3 h at 37‡C. Raji
and HEL cells were radiolabeled with [3H]palmitate at a concentra-
tion of 107/ml under the same conditions. After three washes in
Hanks’ bu¡ered saline solution, the cells were lysed in the presence
of Triton X-100 and immunoprecipitated as previously described [21].
2.5. Analysis of protein interactions
Cells were lysed at a concentration of 2U107/ml in the lysis bu¡er
(1% Brij 97 (Sigma, St. Louis, MO, USA), 10 mM Tris pH 7.4, 150
mM NaCl, 0.02% NaN3, proteases inhibitors, and either 1 mM CaCl2
plus 1 mM MgCl2 or 1 mM EDTA) [21]. After 30 min at 4‡C, the
insoluble material was removed by centrifugation at 10 000Ug and the
cell lysate was precleared for 2 h by addition 1/200 volume heat-
inactivated goat serum and 1/40 volume protein G-Sepharose beads
(Amersham-Pharmacia, Rainham, UK). Proteins were then immuno-
precipitated by adding 1 Wl ascitic £uid and 10Wl protein G-Sepharose
beads to 250 Wl of the lysate. After 2 h incubation at 4‡C under
constant agitation, the beads were washed ¢ve times in lysis bu¡er.
The immunoprecipitates were separated by SDS^polyacrylamide gel
electrophoresis under non-reducing conditions and transferred to a
polyvinylidene di£uoride membrane (Amersham Bioscience, Saclay,
France). Western blotting on immunoprecipitates was performed us-
ing biotinylated mAbs (SYB-1, Z81, TS82b, 11B1G4, TS53) and a
streptavidin-biotinylated horseradish peroxidase complex (Amer-
sham), which was revealed by enhanced chemiluminescence (NEN,
Boston, MA, USA).
2.6. Equilibrium density gradient centrifugation
The cells were lysed as above and equilibrium density gradient
centrifugations were performed as previously described [37]: after lysis
for 30 min on ice, the preparation was mixed with 60% w/w sucrose in
lysis bu¡er without detergent to yield a ¢nal concentration of 40%
sucrose. Then, 0.8 ml of the lysate^sucrose mixture was sequentially
overlaid with 2 ml of 30% sucrose and 1 ml of 4% sucrose prepared in
the same bu¡er, without detergent, and centrifuged at 200 000Ug for
14^16 h in a SW55Ti rotor (Beckman). The gradient was fractionated
in 0.5 ml fractions from the top of the tube and analyzed by Western
blot. All steps were at 4‡C.
3. Results and discussion
3.1. Higher stability of CD9-containing complexes
The use of di¡erent detergents has suggested that the tetra-
spanin web is assembled by the combination of various pri-
mary complexes through tetraspanin/tetraspanin interactions
[1,2]. Whether all tetraspanin/tetraspanin interactions are
equivalent in terms of stability is not known, as they are
similarly conserved or disrupted in the detergents tested so
far (conserved in Brij 97, Brij 98 or CHAPS, disrupted in
Triton X-100, NP-40 or digitonin). While testing di¡erent lysis
conditions we found that supplementing a Brij 97-based lysis
bu¡er with either CaCl2 and MgCl2 (our standard conditions
[18]) or EDTA gave strikingly di¡erent results, depending on
the cell type. In the presence of divalent cations, a strong level
of tetraspanin/tetraspanin interactions was observed. For ex-
ample, in some experiments using Raji cells, up to 50% of
Fig. 1. Higher stability of CD9-containing complexes. Raji, Raji/
CD9 and HEL cells were lysed in Brij 97 lysis bu¡er supplemented
with either 1 mM CaCl2 and 1 mM MgCl2, or 1 mM EDTA as in-
dicated. Immunoprecipitations were performed with anti-tetraspanin
mAb or a CD55 mAb as a control, as indicated at the top of each
lane, and the composition of the immunoprecipitates was analyzed
by Western blot as indicated on the left. The ability of the CD55
mAb to immunoprecipitate the target antigen in the presence or ab-
sence of divalent cations has been checked in independent experi-
ments using biotin-labeled cells.
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CD81 and CD82 associated with CD53 (Fig. 1A). In Raji
(Fig. 1A) or Daudi (not shown) cells, tetraspanin/tetraspanin
interactions (CD81, CD53, CD82, CD151) were totally dis-
rupted in the presence of EDTA. A low level of CD81 could,
however, be observed in some experiments in the CD53 im-
munoprecipitate. This e¡ect of EDTA could be neutralized by
supplementing the lysis bu¡er with higher levels of CaCl2 and
MgCl2 (data not shown). In contrast, in HEL (Fig. 1B) and
HeLa (not shown) cells, only a partial dissociation of the
tetraspanin/tetraspanin complexes was observed. In particular,
the CD9/CD81 association was barely modi¢ed by EDTA.
Contrary to Raji or Daudi cells, HEL and HeLa express
CD9. Thus we examined whether the presence of CD9 could
modify the e¡ect of Brij 97/EDTA. In CD9-transfected Raji
cells (Raji/CD9) the CD9/CD81 association was only slightly
a¡ected by the presence of EDTA and the association of
CD9 with other tetraspanins was partially resistant to Brij
97/EDTA disruption (Fig. 1C). Moreover, the expression of
this molecule rendered other tetraspanin/tetraspanin com-
plexes slightly more resistant. The simplest explanation is
that some of these associations occur indirectly through
CD9. In contrast, overexpression of CD82 in Raji cells did
not modify the sensitivity of tetraspanin/tetraspanin com-
plexes to EDTA (not shown).
Further work will be necessary to determine why divalent
cations in£uence the association of tetraspanins with each
other. They may decrease the ability of the detergent to dis-
rupt these interactions. Alternatively, divalent cations may be
required for optimal tetraspanin/tetraspanin interaction. In
any case, these data point out a higher stability of CD9/tetra-
spanin interactions, and in particular of CD9/CD81.
3.2. Tetraspanins are palmitoylated
We then considered the hypothesis that palmitoylation
could contribute to tetraspanin/tetraspanin interactions.
Among tetraspanins, only CD9 and CD81 were previously
shown to be acylated [35,36]. We have con¢rmed these data
and have found that all tetraspanins tested (CD53, CD63,
CD82, CD151, and CD37) (Fig. 2 and data not shown) in-
corporated [3H]palmitate. In several experiments, CD81 was
the most e⁄ciently labeled. Interestingly, the immature,
poorly glycosylated forms of CD53, CD63 and CD82 were
also labeled with [3H]palmitate.
3.3. CD9 is palmitoylated at any of the four internal
juxtamembrane regions
There is no clear consensus site for palmitoylation of trans-
membrane molecules, which typically takes place at one or
several cysteine residues located adjacent to or just within
the transmembrane domain [32,33]. CD9 contains six such
cysteines located at each of the four internal juxtamembrane
regions and was previously shown to be palmitoylated exclu-
sively through S-acylation [36]. These residues were progres-
sively mutated from the C-terminal extremity to the N-termi-
nal end (Fig. 3A) and intermediate single mutants were also
generated. The di¡erent constructs were expressed in CHO
cells. All mutants were expressed at similar levels on the cell
surface as determined by £ow cytometric analysis (not
shown), showing that palmitoylation is not involved in the
transport of CD9 to the plasma membrane. The recognition
of the mutant molecule with no residual juxtamembrane cys-
teine (CD9plm) by di¡erent mAbs, as well as its ability to
associate with CD9P-1, the major CD9 partner, indicates
that these mutations do not a¡ect the overall conformation
of CD9 (not shown).
Palmitoylation occurs at any of the internal juxtamembrane
regions of CD9 as judged by the progressive diminution of
both relative molecular mass (Fig. 3B,C) and labeling with
[3H]palmitate (Fig. 3D). CD9plm failed to incorporate any
[3H]palmitate and its MW was reduced by 1.5 kDa (Fig.
3C), which is consistent with a previous study showing that
removal of fatty acids from CD9 by hydroxylamine removes
1 kDa [36]. The lower intensity of CD81 labeling as compared
to CD9 in Fig. 3B most likely re£ects a lower expression after
transfection (data not shown).
3.4. Partition of CD9 and CD9plm in DRM
We then investigated whether the palmitoylation of tetra-
spanins played a role in their partition to DRM. Brij 97 ly-
sates of CD9- or CD9plm-transfected Daudi cells were sub-
jected to centrifugation in a sucrose gradient, and the
di¡erent fractions were recovered and analyzed by Western
blot (Fig. 4). When cells were lysed in the presence of divalent
cations, both CD9 and CD9plm were partially recovered in the
low-density fractions, indicating their presence in DRM. The
localization of these molecules in DRM was strongly reduced
Fig. 2. Metabolic labeling of tetraspanins with [3H]palmitate. Raji
and HEL cells were radiolabeled with [3H]palmitate and immuno-
precipitations were performed with di¡erent anti-tetraspanin mAbs
as indicated. The lower bands in the CD63, CD82 and CD53 immu-
noprecipitates most likely correspond to immature forms of the pro-
teins. The identity of the higher band in the CD81 immunoprecipi-
tate collected from Raji cells is unknown.
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after lysis in the presence of EDTA, correlating with the dis-
ruption of most tetraspanin/tetraspanin interactions (Fig. 1).
There was no di¡erence between CD9 and CD9plm. Thus, the
palmitoylation of CD9 does not signi¢cantly contribute to its
presence in DRM.
3.5. E¡ect of cysteine mutations on the association of CD9 with
other tetraspanins
The contribution of CD9 palmitoylation to the interaction
with other tetraspanins was examined in transfected Daudi
cells. As observed in Raji cells, ectopically expressed CD9
associated with CD81 in a Brij 97/EDTA-resistant manner
and rendered other combinations of tetraspanin/tetraspanin
complexes more resistant (Fig. 5). Interactions of CD9plm
with other tetraspanins were detected after lysis in the pres-
ence of Brij 97 and divalent cations but were for the most part
disrupted in the presence of EDTA (including with CD81).
Similar results were observed in CHO cells transiently or sta-
bly expressing CD81 and CD9 or CD9plm. In CHO cells stably
expressing these molecules, and transiently transfected with
CD82, CD82 behaved like CD53 in Daudi cells (data not
shown).
3.6. Concluding remarks
Altogether our data show that the palmitoylation of CD9
contributes to the interaction with other tetraspanins, and in
particular to the higher stability of the CD9/CD81 interaction.
Fig. 3. Analysis of CD9 molecules mutated on one or several juxtamembrane cysteine residues. A: Schematic representation of CD9 with indi-
cation of the internal juxtamembrane cysteine residues, and their change in the mutant molecules. The numbers indicated correspond to the po-
sition of cysteines in the CD9 sequence. B: CHO cells were transiently transfected with CD81 together with di¡erent CD9 constructs and meta-
bolically labeled with [3H]palmitate. Cells were lysed and immunoprecipitations with CD9 and CD81 mAbs were performed. The extent of
[3H]palmitate labeling was determined by £uorography. A fraction of the immunoprecipitates was analyzed by immunoblotting using biotin-
labeled CD9 or CD81 mAbs as indicated. C: Same as B, except that CHO cells stably expressing CD9 or CD9plm and CD81 were analyzed.
D: The intensity of [3H]palmitate labeling of each mutant was estimated by densitometry and normalized according to the amount of protein
determined by Western blot. The graph shows the labeling of each mutant relative to CD9 as a function of the number of mutated cysteines.
The line corresponds to the expected values for an attachment of a palmitate on each CD9 juxtamembrane cysteine.
Fig. 4. Buoyant properties of CD9 and CD9plm. Daudi cells express-
ing CD9 or CD9plm were lysed with Brij 97 bu¡er supplemented
with either 1 mM CaCl2 plus 1 mM MgCl2, or 1 mM EDTA as in-
dicated. The extracts were directly subjected to equilibrium density
gradient centrifugation. Gradient fractions were collected and ana-
lyzed by Western blot using the CD9 mAb SYB-1. The fractions
are indicated at the top of each lane. Fractions 1^3 correspond to
low-density fractions (L) and 5^8 to high-density fractions (H).
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The observation that CD9plm interacts with other tetraspanins
in the milder condition (in the presence of divalent cations)
indicates the participation of additional mechanisms. It is un-
clear why the other tetraspanin/tetraspanin interactions are
disrupted in the presence of EDTA in spite of the palmitoy-
lation of the molecules. It is possible that the palmitoylation is
involved but is not su⁄cient to stabilize the complexes under
these conditions. In this regard, CD9 and CD81 may be the
most palmitoylated tetraspanins, since both have six juxta-
membrane cysteine residues as compared to four for CD82
and three for CD53. Moreover, CD81 was found to incorpo-
rate more [3H]palmitate than the other tetraspanins although
this may also re£ect a di¡erent turn-over or a di¡erent sub-
cellular localization (at least for a certain fraction of the mol-
ecule). Alternatively, among the tetraspanins studied here,
CD81 is the only one that lacks N-glycans, and only a minor
fraction of CD9 has such modi¢cations [36]. It is possible that
the presence of N-glycans on other tetraspanins contributes to
a better dispersion of the tetraspanin/tetraspanin complexes in
the more stringent conditions.
The observation that CD9 can be induced to redistribute
into the high-density fractions of sucrose gradients by EDTA
while maintaining the association with CD81 shows that these
molecules interact outside DRM. This association is itself de-
pendent on CD9 palmitoylation since it is lost upon mutation
of palmitoylation sites. This clearly indicates that palmitoyla-
tion of CD9 plays a role in the interaction with CD81 (and
probably other tetraspanins) independently of the interaction
with DRM. To our knowledge, this is the ¢rst demonstration
that acylation contributes to the formation and/or stability
of multimolecular complexes involving transmembrane mol-
ecules. It is possible that tetraspanins interact through lipids,
and that their palmitoylation facilitates this interaction. In-
deed, a photoactivatable GM3 was recently found to cross-
link to CD9 [38], and we speculate that GM3 and possibly
other lipids may contribute to the formation of tetraspanin/
tetraspanin complexes. We propose that when a su⁄cient level
of tetraspanin interactions is achieved, the tetraspanins parti-
tion into DRM.
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